Patents Examined by Yunsoo Kim
  • Patent number: 10413481
    Abstract: The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, NEUPOGEN (filgrastim), NEULASTA (pegfilgrastim), EPOGEN (epoetin alfa) or ENBREL (etanercept).
    Type: Grant
    Filed: September 4, 2015
    Date of Patent: September 17, 2019
    Assignee: Corning Incorporated
    Inventors: Wendell Porter Weeks, Robert Anthony Schaut, Steven Edward DeMartino, John Stephen Peanasky
  • Patent number: 10413483
    Abstract: The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, PROCRIT (epoetin alfa), REMICADE (Infliximab) or DORIBAX (doripenem).
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: September 17, 2019
    Assignee: Corning Incorporated
    Inventors: Wendell Porter Weeks, Robert Anthony Schaut, Steven Edward DeMartino, John Stephen Peanasky
  • Patent number: 10413482
    Abstract: The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient.
    Type: Grant
    Filed: September 4, 2015
    Date of Patent: September 17, 2019
    Assignee: Corning Incorporated
    Inventors: Wendell Porter Weeks, Robert Anthony Schaut, Steven Edward DeMartino, John Stephen Peanasky
  • Patent number: 10391055
    Abstract: Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: August 27, 2019
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Svetomir N. Markovic, Wendy K. Nevala
  • Patent number: 10376582
    Abstract: The invention provides buffered formulations of adalimumab. The formulations comprise a buffer comprising an acetate salt, mannitol, glacial acetic acid, sodium chloride, and polysorbate 80. The formulations have an acidic pH, and enhance the thermal, conformational and colloidal stability of antibodies, including the adalimumab antibody.
    Type: Grant
    Filed: October 16, 2014
    Date of Patent: August 13, 2019
    Assignee: Outlook Therapeutics, Inc.
    Inventors: John Cini, Athena Nagi, Maria Taddei
  • Patent number: 10377831
    Abstract: The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-CD20 antibody, such as e.g. Rituximab, Ocrelizumab, or HuMab<CD20>, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-CD20 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The said formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. ?,?-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.
    Type: Grant
    Filed: November 18, 2015
    Date of Patent: August 13, 2019
    Assignee: Genentech, Inc.
    Inventors: Michael Adler, Hanns-Christian Mahler, Oliver Boris Stauch
  • Patent number: 10370456
    Abstract: The present disclosure provides a process for concentrating proteins including an ultrafiltering, a diafiltering, and a second ultrafiltering sequence, at elevated temperatures, such as above about 30° C. The disclosure also includes a process for preparing highly concentrated antibody compositions, and highly concentrated antibody products.
    Type: Grant
    Filed: April 21, 2014
    Date of Patent: August 6, 2019
    Assignees: GENENTECH, INC., NOVARTIS AG
    Inventor: Charles M. Winter
  • Patent number: 10357482
    Abstract: Disclosed are methods and related compositions for concomitantly, locally administering immunosuppressants and doses of therapeutic macromolecules for reducing Type I and Type IV hypersensitivity.
    Type: Grant
    Filed: May 2, 2014
    Date of Patent: July 23, 2019
    Assignee: Selecta Biosciences, Inc.
    Inventor: Roberto A. Maldonado
  • Patent number: 10358488
    Abstract: The invention relates to a pharmaceutical composition comprising an interleukin-13 antibody, more particularly a monoclonal interleukin-13 antibody, especially a human interleukin-13 monoclonal antibody, to a process for purifying said antibody and to the use of said composition in treating interleukin-13 related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis, chronic obstructive pulmonary disease, scleroderma, inflammatory bowel disease and Hodgkin's lymphoma, particularly asthma.
    Type: Grant
    Filed: July 14, 2015
    Date of Patent: July 23, 2019
    Assignee: MEDIMMUNE LIMITED
    Inventors: Claire Louise Hope, Karen Bannister, Brendan Cormick Fish, Jeanette Elizabeth Langstone
  • Patent number: 10357483
    Abstract: Disclosed are dosings of therapeutic macromolecules and immunosuppressants, in some embodiments attached to synthetic nanocarriers, in combination with dosings of therapeutic macromolecules without synthetic nanocarriers, and related methods that provide reduced humoral immune responses.
    Type: Grant
    Filed: May 2, 2014
    Date of Patent: July 23, 2019
    Assignee: Selecta Biosciences, Inc.
    Inventors: Roberto A. Maldonado, Takashi Kei Kishimoto
  • Patent number: 10344261
    Abstract: The present invention provides an immunomodulatory compound comprising a carbohydrate polymer comprising mannose, wherein the carbohydrate polymer is conjugated to at least one immune modulator. The present invention also provides for the use of this compound in immunomodulatory compositions for vaccination and gene therapy methods, together with processes for its preparation.
    Type: Grant
    Filed: November 9, 2012
    Date of Patent: July 9, 2019
    Assignee: ASCEND BIOPHARMACEUTICALS LTD
    Inventors: Geoffrey Alan Pietersz, Clement Leong
  • Patent number: 10342876
    Abstract: The present disclosure provides a stable protein composition containing a surfactant and having less than 400 subvisible particles of 10 microns or greater diameter per container, or less than 10,000 subvisible particles of 2 microns or greater per container. A method of manufacturing such a stable protein composition is disclosed, which includes a unit of operation that removes or decreases an esterase activity that degrades the surfactant. The unit of operation may be hydrophobic interaction chromatography or filtration, mixed mode chromatography, or the like.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: July 9, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Hanne Bak, John Mattila, Ning Li, Xiaolin Tang, Daniel Dix, Chen Li, William Markis
  • Patent number: 10335395
    Abstract: This invention relates to methods that provide immunosuppressants and therapeutic macromolecules that are administered within a pharmacodynamically effective window of the immunosuppressants to induce immune tolerance to the therapeutic macromolecules. The methods allow shifting the immune response in favor of tolerogenic immune response development specific to the therapeutic macromolecule.
    Type: Grant
    Filed: May 2, 2014
    Date of Patent: July 2, 2019
    Assignee: Selecta Biosciences, Inc.
    Inventor: Takashi Kei Kishimoto
  • Patent number: 10322084
    Abstract: Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.
    Type: Grant
    Filed: August 1, 2016
    Date of Patent: June 18, 2019
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Svetomir N. Markovic, Wendy K. Nevala
  • Patent number: 10316095
    Abstract: Formulations of anti-VLA-1 antibodies are described.
    Type: Grant
    Filed: February 14, 2013
    Date of Patent: June 11, 2019
    Assignee: Santarus, Inc.
    Inventors: Adam Jeremy Fowler, Craig Michael Bowe, Wayne Curtis Yount, Nathan Jeremy Cobb, Timothy Martin Kelly
  • Patent number: 10308716
    Abstract: The invention relates to a method for producing polyclonal antibodies against an antigenic target protein which comprises inducing an immune response in a host by applying an immunogenic composition comprising membrane vesicles incorporating said antigenic target protein to said host and obtaining antibodies against said target protein from the host's serum.
    Type: Grant
    Filed: September 24, 2014
    Date of Patent: June 4, 2019
    Assignee: Fraunhofer-Gesellschaft zur Foerderung der angewandten Forschung e. V.
    Inventors: Marlitt Stech, Katja Hanack, Katrin Messerschmidt, Stefan Kubick
  • Patent number: 10308969
    Abstract: The present invention provides a method for producing a multimeric protein composed of a monomeric protein, wherein the monomeric protein is obtained by fusing a protein having an immunoglobulin fold structure to a protein that can serve as a subunit structure, the method including the steps of: (A) preparing the monomeric protein having an insoluble granular form in cells of a microorganism; (B) solubilizing the monomeric protein prepared in step (A) with an aqueous solution containing lauroyl-L-Glu; (C) diluting a solution obtained in step (B) in a buffer containing arginine hydrochloride to lower a concentration of lauroyl-L-Glu; and (D) replacing a solvent of a solution obtained in step (C) with a buffer using gel filtration chromatography or the like.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: June 4, 2019
    Assignee: AJINOMOTO CO., INC.
    Inventors: Daisuke Ejima, Haruna Sato, Kouhei Tsumoto, Masayo Date
  • Patent number: 10300016
    Abstract: Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: May 28, 2019
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Svetomir N. Markovic, Wendy K. Nevala
  • Patent number: 10286072
    Abstract: The invention provides aqueous pharmaceutical adalimumab compositions suitable for long-term storage of adalimumab, methods of manufacture of these compositions, methods of administration, and kits containing same.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: May 14, 2019
    Assignee: Coherus Biosciences, Inc.
    Inventors: Mark Manning, Robert W. Payne
  • Patent number: 10286071
    Abstract: The invention provides aqueous pharmaceutical adalimumab compositions suitable for long-term storage of adalimumab, methods of manufacture of these compositions, methods of administration, and kits containing same.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: May 14, 2019
    Assignee: Coherus Biosciences, Inc.
    Inventors: Mark Manning, Robert W. Payne